title: Did narcolepsy occur following administration of AS03-adjuvanted A(H1N1) pandemic vaccine in Ontario, Canada? A review of post-marketing safety surveillance data.
authors.affiliation: Public Health Ontario, Toronto, Ontario, Canada.
authors.forename: T
authors.initials: T
authors.lastname: Harris
authors.forename: K
authors.initials: K
authors.lastname: Wong
authors.forename: L
authors.initials: L
authors.lastname: Stanford
authors.forename: J
authors.initials: J
authors.lastname: Fediurek
authors.forename: N
authors.initials: N
authors.lastname: Crowcroft
authors.forename: Sl
authors.initials: S
authors.lastname: Deeks
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007223:Infant; D053118:Influenza A Virus, H1N1 Subtype / Q000276:immunology*; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology; D007251:Influenza, Human / Q000453:epidemiology / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D009290:Narcolepsy / Q000453:epidemiology / Q000209:etiology*; D009864:Ontario / Q000453:epidemiology; D058873:Pandemics / Q000517:prevention & control; D011358:Product Surveillance, Postmarketing; D018571:Sentinel Surveillance
chemical_list: D000276:Adjuvants, Immunologic; D007252:Influenza Vaccines